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Background/Objectives: There is a scarcity of recent data on the burden of herpes zoster (HZ) and post-
herpetic neuralgia (PHN) in Southeast Asia. We evaluated the prevalence, demographics, and disease
burden of HZ and PHN in patients aged  50 years seen at a tertiary dermatological referral center, the
National Skin Centre (NSC), Singapore.
Methods: We carried out a retrospective cohort analysis of NSC patient electronic medical records
spanning >3 years from January 2010 to March 2013. Data on patient demographics, clinical charac-
teristics, and medical management were collected.
Results: A total of 347 cases of HZ or PHN were included in this study. The mean age was 66.5 years with
equal proportions of men and women. The majority of patients (85.6%) were of Chinese ethnicity. Pa-
tients presented to the NSC at various disease stages including acute HZ (83.0%), subacute HZ (10.7%), or
PHN (6.3%). The most commonly affected anatomic site was thoracic dermatome (41.2%) and the most
common prodromal symptomwas pain (81.8%). In addition, pain was present in various stages of HZ, and
it was the most unbearable symptom experienced during illness (85.5%). Patients in the older age group
were more likely to suffer from pain for 6 months than patients in the younger age group. Most of the
patients received antiviral treatment including acyclovir (70.9%) and valaciclovir (13.5%). Among all the
patients, 85.0% received analgesia with the most common drugs being amitriptyline (25.4%) and gaba-
pentin (21.9%). PHN led to signiﬁcantly higher economic burden with a total cost of 414.69 Singapore
dollars per patient versus 267.26 Singapore dollars for a non-PHN patient.
Conclusion: HZ and PHN cause a signiﬁcant clinical and economic burden in Singapore.
Copyright © 2015, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Herpes zoster (HZ), also called shingles, is a common infection
caused by the reactivation of varicella-zoster virus (VZV) that is
latent in the spinal and cranial sensory ganglia from the time of
primary VZV infection (chickenpox).1e4 A vesicular skin rash in they have no ﬁnancial or non-
atter or materials discussed
1 Mandalay Road, 308205,
cal Association. Published by Elsevaffected dermatome, commonly accompanied by acute pain, char-
acterizes the acute phase of HZ. HZ is associated with pain, which
occurs in various disease stages, either preceding, associated with,
following, or enduring for several weeks after the HZ skin eruption.
The most frequent debilitating complication is postherpetic neu-
ralgia (PHN).5e9 PHNmay persist for years and is often refractory to
treatment.6
The incidence and severity of HZ and PHN increasewith age, and
is associated with a progressive decline in cell immunity to
VZV.10e12 Antiviral medication, if given early in acute HZ, is able to
reduce the severity and duration of the acute blistering eruptions,
but has not been found to prevent the development of PHN.4,8 The
zoster vaccine, Zostavax (Merck, USA), has been shown to decreaseier Taiwan LLC. All rights reserved.
Table 1 Number and percentage of herpes zoster patients by age, sex, and ethnicity
seen in the Singapore National Skin Centre from January 2010 to March
2013.
Age (y) 50e59 60e69 70e79 80þ Total
Male 53 (15.3) 61 (17.6) 43 (12.4) 15 (4.3) 172 (49.6)
Female 40 (11.5) 63 (18.2) 48 (13.8) 24 (6.9) 175 (50.4)
Chinese 73 (21.0) 112 (32.3) 76 (21.9) 36 (10.4) 297 (85.6)
Malay 8 (2.3) 3 (0.9) 5 (1.4) 1 (0.3) 17 (4.9)
Indian 6 (1.7) 4 (1.2) 6 (1.7) 0 (0.0) 16 (4.6)
Others 6 (1.7) 5 (1.4) 4 (1.2) 2 (0.6) 17 (4.9)
Total 93 (26.8) 124 (35.7) 91 (26.2) 39 (11.2) 347 (100.0)
Data are presented as n (%).
Figure 1 Stage of herpes zoster (HZ) stratiﬁed by age.
Figure 2 Anatomic involvement of herpes zoster by site.
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patients.13e16 Zostavax has been approved for use in Singapore for
adults aged 50 years of age since 2008. Studies on the prevalence
and disease burden of HZ and PHN have been published from
different countries including Australia,17 Italy,18 Taiwan,19 France,20
Germany,21 Thailand,22 Belgium,23 the United Kingdom,24 Spain,25
Sweden,26 and South Korea.27 The most recent study on disease
burden of HZ and PHN in Singapore dates back to 1997.28
Methods
We carried out a retrospective cohort study of patients diagnosed
as having HZ or PHN in the National Skin Centre (NSC) who were
aged  50 years from 2010 to 2013. The NSC is the largest public
dermatology clinic in Singapore, with >1200 attendances/d. Clin-
ical data and detailed treatment history were retrieved from elec-
tronic medical records. Data of demographics, presenting stage,
anatomic site involvement, prodrome, impact of illness, treatment
including antiviral medication and analgesics, comorbidities, and
disease burden including economic burden due to HZ and PHN
were analyzed.
The diagnosis of HZ was based on the characteristic clinical
presentation of a dermatomal blistering eruption. Zoster-associated
pain was deﬁned as prodromal (pain occurring before the onset of
blistering eruptions), acute pain (pain within 1 month of onset),
subacute pain (painwithin 1 month to 3 months of onset), and PHN
(pain appearing or persisting 3 months after the onset of blistering
eruptions).
Costs were presented in Singapore dollars (S$). In 2013, S$1 was
equal to approximately US$0.8. The overall economic burden due
to HZ included healthcare cost and indirect costs. Healthcare cost
was calculated as the sum of total treatment cost, consultation
fees, and hospitalization fees. Indirect cost due to absenteeism
from work was calculated as the number of days of medical leave
(taken by patients aged  65 years) multiplied by daily wage
quoted from the Comprehensive Labour Force Survey (2012),29
from which the daily wage of S$160.6 was estimated from a
monthly income of S$3480.
This study was approved by the National Healthcare Group
Domain Speciﬁc Review Board ethics committee. Statistical analysis
was performed using SAS version 9.2 (SAS Institute Inc., Cary, NC,
USA). Descriptive statistics were generated for all variables in the
study. The two-sided t test was used to testify the difference in
group means at the 5% signiﬁcance level.
There was an average of 150e200 HZ patients seen in the NSC
each year from 2003 to 2012 with the majority being of Chinese
ethnicity. Based on the age distribution data of HZ from 2003 to
2012, we focused this study on those patients aged  50 years who
were seen during period from January 2010 to March 2013.
Results
A total of 347 patients were included in this study. Table 1 shows
the demographic data of our study cohort. The majority were
Chinese (85.6%) with a small number of Malay, Indian, and other
ethnicities (4.9%, 4.6%, and 4.9% retrospectively). These proportions
reﬂected the general ethnic distribution in Singapore. Approxi-
mately half of the patients (50.6%) were women. The mean age of
patients with HZ in our cohort was 66.5 years.
Because the NSC is a tertiary dermatological referral center,
most of the patients would have sought treatment at either primary
care or the emergency department before their ﬁrst consultation,
and therefore presented at the NSC in various stages of HZ. In this
study, the majority of patients presented as acute HZ (83.0%), fol-
lowed by subacute HZ (10.7%) and then PHN (6.3%; Figure 1).The frequency of the anatomic involvement of HZ is shown in
Figure 2. The thoracic (41.2%) region was the most commonly
affected region in our patients. Other common affected regions
were the lumbar (17.3%), cervical (16.4%), ophthalmic (11.0%)
maxillary (7.5%), and sacral (6.9%) regions, and the limbs (0.1%).
Most of our patients experienced prodromal symptoms. In this
study, the various prodromal symptoms were pain, itch, and
insomnia (81.8%, 15.9% and 4.3% respectively). After onset of HZ,
patients reported that the most unbearable symptoms experienced
were pain or discomfort (85.9%), blistering rashes followed by
scarring (44.4%), and insomnia or sleep disturbance (4.0%).
Table 2 shows that the majority of patients (84.4%, n ¼ 293) in
this study received antiviral treatment, most commonly with
acyclovir (70.9%). Approximately 55.6% of patients required treat-
ment for pain control; the most commonly used medications were
amitriptyline (25.4%), gabapentin (21.9%), tramadol (16.4%), para-
cetamol (13.5%), and oral nonsteroidal anti-inﬂammatory drugs
(7.8%; Table 2). Due to the signiﬁcant impact of pain on patients'
Table 2 Antiviral treatment and analgesia treatment for herpes zoster.
Antiviral treatment No. of patients %
Acyclovir 246 70.9
Valaciclovir 47 13.5
Total 293 84.4
Analgesia treatment No. of patients %
Amitriptyline 88 25.4
Gabapentin 76 21.9
Tramadol 57 16.4
Paracetamol 47 13.5
Oral NSAIDs 27 7.8
Total 295 85.0
NSAIDs ¼ nonsteroidal anti-inﬂammatory drugs.
Figure 4 Economic burden of herpes zoster.
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groups (Figure 3). Approximately 78.0% of patients presenting with
PHNwere aged 60 years. Older patients weremore likely to suffer
pain for >6months and their painwas more severe. The percentage
of patients suffering pain for >6 months were 2.2%, 2.4%, 6.5%, and
7.7% in the age groups of 50e59 years, 60e69 years, 70e79 years,
and  80 years, respectively.
The overall economic burden caused by HZ includes treatment
cost including antiviral and analgesia, consultation fee, hospitali-
zation cost, and indirect cost due to absenteeism from work. The
overall costs were highest in the labor productive age group, due to
increased signiﬁcant indirect costs because of absenteeism from
work. The indirect costs were highest in the age group 50e59 years
(S$ 210.56) followed by the age group 60e69 years (S$63.98;
Figure 4).Figure 3 Duration of herpes zoster-relOur data showed that comorbidities such as diabetes, hyper-
tension, dyslipidemia, and ischemia heart disease were common in
patients. The prevalence of diabetes and ischemia heart diseasewas
highest in the age 70e79 years group (23.1% and 8.8%, respectively).
The prevalence of both hypertension and hyperlipidemia was
highest in the age > 80 years group (51.3% and 36%, respectively).
Our study showed that PHN resulted in signiﬁcantly higher
costs. The mean direct cost including prescription, consultation,
and hospitalization for PHN patients was S$359.48 whereas the
mean direct cost for non-PHN patients was S$186.70. The difference
in direct cost between patients with and without PHN, S$172.78,
can be considered as the additional cost driven by PHN.ated pain stratiﬁed by age group.
Table 3 Comparison of economic burden (Singapore dollars) between postherpetic
neuralgia (PHN) and non-PHN.
Economic burden/patient characteristics PHN
(n ¼ 32)
Non-PHN
(n ¼ 315)
Total medication cost 47.53 23.99
Consultation fees (incl. government subsidy) 253.26 133.76
Hospitalization cost (incl. government subsidy) 58.69 28.95
Total direct cost 359.48 186.7
Total indirect cost (productivity loss) 55.21 80.56
Total cost (direct þ indirect) 414.69 267.26
*The t test shows the difference in the direct cost between PHN and non-PHN pa-
tients is 172.8 Singapore dollars at the 5% signiﬁcance level (p ¼ 0.008).
Q. Chen et al. / Dermatologica Sinica 33 (2015) 201e205204In general, an individual episode of HZ costs Singapore society
S$340, including pharmaceutical treatments, consultation provided
by medical professionals, hospitalization, and productivity loss due
to the absenteeism fromwork. It might, therefore, be more costly to
treat HZ than the cost of prevention or early diagnoses and treat-
ment. Moreover, patients with PHN incurred 1.92 times more costs
than non-PHN patients; this was statistically signiﬁcant (Table 3).
Discussion
Our study shows that HZ is a debilitating disease causing signiﬁcant
clinical and economic burden to patients in Singapore. PHN led to
signiﬁcantly higher costs with a total cost of S$414.69/patient
compared with S$267.26 for a non-PHN patient with HZ. One
known HZ study from Singapore in 1997 showed that HZ tended to
affect the older age groups and PHN was signiﬁcantly more com-
mon in elderly patients.28 This study provides updated knowledge
related to the burden of herpes zoster in Singapore. Cost analysis
including direct and indirect costs was not studied in the previous
published paper.28
In this study, 84.4% of patients received early antiviral treat-
ment. Early antiviral treatment, preferably within 72 hours of onset,
reduces the severity and duration of the acute blistering eruptions.
It is therefore important to train general practitioners to recognize
the early symptoms and signs of HZ in order for the antivirals to be
administered early. Patients should also be educated to identify the
prodromal symptoms and skin eruptions related to HZ, and to seek
early medical attention.4,8
Our study showed that pain is the most debilitating HZ symp-
tom and that pain occurs at each stage of the disease including the
prodrome, acute, subacute, and PHN stage. Thus adequate pain
control should be administered at all stages of HZ. In this study,
approximately 85% of patients in this study received analgesia.
Although both antivirals and analgesia are important, they can
be expensive. Besides the expenses from medication and consul-
tation fees, other costs include hospitalization cost for severe cases
requiring inpatient care and indirect cost due to absenteeism from
work. In our study, indirect cost was estimated as the number of
days of medical leave multiplied by daily wage quoted from ofﬁcial
statistics for patients aged  65 years (retirement age in Singapore
is 65 years). Overall costs were highest in the working age group,
due to increased signiﬁcant indirect costs related to work
absenteeism.
Our study showed that elderly patients were more likely to
suffer from pain for >6 months. Approximately 78% of the patients
presenting with PHN were aged  60 years. Previous studies have
also indicated that older adults had a signiﬁcantly higher risk of
developing PHN.11e13 In light of the growing elderly population in
Singapore (by 2050, approximately 49% of Singaporeans will be
aged 65þ years) and increased HZ prevalence increasing with age,
the ﬁnding of greater severity of illness and longer pain duration in
older patients is highly important.This study had several limitations. Data were collected only
from NSC electronic medical records, and not from primary phy-
sicians. Additional healthcare costs and days of medical leave may
have been obtained from the general practitioner. Estimations of
median income and government subsidies were obtained from the
Comprehensive Labour Force Survey 201229 and may not be
applicable to all patients. The impact of presenteeism or reduced
productivity while at work due to discomfort and pain was difﬁcult
to quantify, but also represents an increased indirect cost.
This study provides a better understanding of the burden of HZ
and PHN in patients aged 50 years. HZ and PHN were found to be
common and debilitating diseases. Patients aged  60 years were
particularly at an increased risk of severe and long-lasting pain
which often affects health-related quality of life and daily activities.
The overall costs were highest in the working age group, due to
increased signiﬁcant indirect costs as a result of work absenteeism.
The zoster vaccine has been reported to reduce morbidity from
HZ and PHN markedly among older patients.13e16 The signiﬁcant
clinical and economic burden of HZ indicated in our study un-
derscores the importance of HZ vaccination in high-risk patients,
especially for elderly adults who have higher HZ risk and are more
likely to suffer from chronic zoster-associated pain.Acknowledgments
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